Literature DB >> 24632618

IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction.

C Rupp1, M Scherzer2, A Rudisch3, C Unger2, C Haslinger3, N Schweifer3, M Artaker4, H Nivarthi5, R Moriggl5, M Hengstschläger2, D Kerjaschki1, W Sommergruber3, H Dolznig2, P Garin-Chesa6.   

Abstract

The activated tumor stroma participates in many processes that control tumorigenesis, including tumor cell growth, invasion and metastasis. Cancer-associated fibroblasts (CAFs) represent the major cellular component of the stroma and are the main source for connective tissue components of the extracellular matrix and various classes of proteolytic enzymes. The signaling pathways involved in the interactions between tumor and stromal cells and the molecular characteristics that distinguish normal 'resting' fibroblasts from cancer-associated or '-activated' fibroblasts remain poorly defined. Recent studies emphasized the prognostic and therapeutic significance of CAF-related molecular signatures and a number of those genes have been shown to serve as putative therapeutic targets. We have used immuno-laser capture microdissection and whole-genome Affymetrix GeneChip analysis to obtain transcriptional signatures from the activated tumor stroma of colon carcinomas that were compared with normal resting colonic fibroblasts. Several members of the Wnt-signaling pathway and gene sets related to hypoxia, epithelial-to-mesenchymal transition (EMT) and transforming growth factor-β (TGFβ) pathway activation were induced in CAFs. The putative TGFβ-target IGFBP7 was identified as a tumor stroma marker of epithelial cancers and as a tumor antigen in mesenchyme-derived sarcomas. We show here that in contrast to its tumor-suppressor function in epithelial cells, IGFPB7 can promote anchorage-independent growth in malignant mesenchymal cells and in epithelial cells with an EMT phenotype when IGFBP7 is expressed by the tumor cells themselves and can induce colony formation in colon cancer cells co-cultured with IGFBP7-expressing CAFs by a paracrine tumor-stroma interaction.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24632618     DOI: 10.1038/onc.2014.18

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

1.  Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma.

Authors:  Yohei Mano; Sachiyo Yoshio; Hirotaka Shoji; Shimagaki Tomonari; Yoshihiko Aoki; Nobuyoshi Aoyanagi; Toru Okamoto; Yoshiharu Matsuura; Yosuke Osawa; Kiminori Kimura; Kyohei Yugawa; Huanlin Wang; Yoshinao Oda; Tomoharu Yoshizumi; Yoshihiko Maehara; Tatsuya Kanto
Journal:  J Gastroenterol       Date:  2019-04-02       Impact factor: 7.527

2.  Insulin-like growth factor binding protein 7 and tissue inhibitor of metalloproteinases-2: differential expression and secretion in human kidney tubule cells.

Authors:  David R Emlet; Nuria Pastor-Soler; Allison Marciszyn; Xiaoyan Wen; Hernando Gomez; William H Humphries; Seth Morrisroe; Jacob K Volpe; John A Kellum
Journal:  Am J Physiol Renal Physiol       Date:  2016-12-21

3.  Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms.

Authors:  C Unger; N Kramer; D Unterleuthner; M Scherzer; A Burian; A Rudisch; M Stadler; M Schlederer; D Lenhardt; A Riedl; S Walter; A Wernitznig; L Kenner; M Hengstschläger; J Schüler; W Sommergruber; H Dolznig
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

4.  Proteomic identification of a marker signature for MAPKi resistance in melanoma.

Authors:  Verena Paulitschke; Ossia Eichhoff; Christopher Gerner; Philipp Paulitschke; Andrea Bileck; Thomas Mohr; Phil F Cheng; Alexander Leitner; Emmanuella Guenova; Ieva Saulite; Sandra N Freiberger; Anja Irmisch; Bernhard Knapp; Nina Zila; Theodora-Pagona Chatziisaak; Jürgen Stephan; Joanna Mangana; Rainer Kunstfeld; Hubert Pehamberger; Ruedi Aebersold; Reinhard Dummer; Mitchell P Levesque
Journal:  EMBO J       Date:  2019-06-26       Impact factor: 11.598

Review 5.  Role of cancer-associated fibroblasts in invasion and metastasis of gastric cancer.

Authors:  Yu Yan; Li-Feng Wang; Rui-Fen Wang
Journal:  World J Gastroenterol       Date:  2015-09-07       Impact factor: 5.742

6.  Tissue and serum IGFBP7 protein as biomarker in high-grade soft tissue sarcoma.

Authors:  Maria Serena Benassi; Laura Pazzaglia; Chiara Novello; Irene Quattrini; Serena Pollino; Giovanna Magagnoli; Piero Picci; Amalia Conti
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

Review 7.  Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment.

Authors:  Luke Bu; Hideo Baba; Naoya Yoshida; Keisuke Miyake; Tadahito Yasuda; Tomoyuki Uchihara; Patrick Tan; Takatsugu Ishimoto
Journal:  Oncogene       Date:  2019-02-28       Impact factor: 9.867

8.  An Optimized Method to Isolate Human Fibroblasts from Tissue for ex vivo Analysis.

Authors:  Sara Waise; Rachel Parker; Matthew J J Rose-Zerilli; David M Layfield; Oliver Wood; Jonathan West; Christian H Ottensmeier; Gareth J Thomas; Christopher J Hanley
Journal:  Bio Protoc       Date:  2019-12-05

9.  High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts.

Authors:  Albin Rudisch; Matthew Richard Dewhurst; Luminita Gabriela Horga; Nina Kramer; Nathalie Harrer; Meng Dong; Heiko van der Kuip; Andreas Wernitznig; Andreas Bernthaler; Helmut Dolznig; Wolfgang Sommergruber
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

10.  Inhibitory effect of insulin-like growth factor-binding protein-7 (IGFBP7) on in vitro angiogenesis of vascular endothelial cells in the rat corpus luteum.

Authors:  Kazuhiro Tamura; Mikihiro Yoshie; Keisuke Hashimoto; Eiichi Tachikawa
Journal:  J Reprod Dev       Date:  2014-09-09       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.